We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03010046

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Single Dose Study of ANX005 in Healthy Volunteers
Scientific title
A Phase 1, Randomized, Placebo-controlled, Double Blind, Single, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ANX005 Monotherapy and ANX005 in Combination With IVIg in Healthy Volunteers
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Safety and Tolerability in Healthy Volunteers 0 0
Condition category
Condition code

Study type
Description of intervention(s) / exposure
Treatment: Drugs - ANX005
Treatment: Drugs - IVIg
Treatment: Drugs - Placebos

Experimental: ANX005 Monotherapy - ANX005 intravenous infusion

Experimental: ANX005 and IVIg Combination Therapy - ANX005 intravenous infusion in combination with intravenous immunoglobulin (IVIg)

Placebo Comparator: Placebo - Placebo intravenous infusion

Treatment: Drugs: ANX005
Single ascending dose intravenous infusion

Treatment: Drugs: IVIg
IVIg infusion in Cohorts 4b and 5b only. Randomized to ANX005 followed by IVIg or placebo followed by IVIg.

Treatment: Drugs: Placebos
0.9% saline intravenous infusion

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03 - Safety is assessed throughout the study. Day 43 is the last visit.
Timepoint [1] 0 0
Day 43
Secondary outcome [1] 0 0
Peak plasma concentration
Timepoint [1] 0 0
Day 43
Secondary outcome [2] 0 0
Determine effective dose of ANX005 - Percent of subjects with a biologic response, defined as a reduction of serum CH50 percent change from baseline at 21 and 28 days after the first ANX005 infusion
Timepoint [2] 0 0
Day 43
Secondary outcome [3] 0 0
Area under the plasma concentration versus time curve (AUC)
Timepoint [3] 0 0
Day 43
Secondary outcome [4] 0 0
Terminal half-life
Timepoint [4] 0 0
Day 43

Key inclusion criteria
- Male and females 18 years and older

- Females must be postmenopausal, surgically sterilized, or willing and able to use 2
methods of contraception throughout the study and for 1 month after the final study

- Willing and able to undergo vaccination if not vaccinated recently
Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- History of any autoimmune disease, meningitis, septicemia or pneumonia

- History of hypercoagulable diseases, hyperviscosity, thrombosis, renal dysfunction or
acute renal failure

- Known genetic deficiencies of the complement cascade system

- History of conditions whose symptoms and effects could alter protein catabolism or IgG
utilization, e.g. protein-losing enteropathies or nephrotic syndrome

- Body weight less than 50 kg or greater than 100 kg

- Hypersensitivity or allergic reactions to any excipients in the ANX005 drug product

- (Cohorts 4b and 5b) Known selective IgA deficiency or presence of antibodies to IgA at

- (Cohorts 4b and 5b) Prior reaction or hypersensitivity to blood products, including
IVIg or any of the excipients in IVIg.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Nucleus Network - Melbourne
Recruitment postcode(s) [1] 0 0
- Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Annexon, Inc.

Ethics approval
Ethics application status

Brief summary
This is a single-center, randomized, double-blind, placebo-controlled, ascending,
single-infusion, sequential group study. Single, ascending doses will be administered to
approximately 64 subjects, with an option for 1 additional multi-dose cohort in approximately
8 subjects. The primary objective is to evaluate the safety of ANX005 administered as an
intravenous infusion as a single agent and in combination with intravenous immunoglobulin
(IVIg). The optional multi-dose cohort will evaluate either additional subjects at the
maximum tolerated dose or ANX005 administered as 2 infusions.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Sandy Calman, MD
Address 0 0
Annexon Medical Monitor
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT03010046